Ophthalmology. Glaucoma最新文献

{"title":"Factors Associated with Goniotomy Outcomes in the United States","authors":"Julia H. Joo MD, MPH,&nbsp;Huijun Xiao MS,&nbsp;Adam L. Rothman MD,&nbsp;James Bena MS,&nbsp;Shannon Morrison MS,&nbsp;Flora Lum MD,&nbsp;Ang Li MD","doi":"10.1016/j.ogla.2026.01.014","DOIUrl":"10.1016/j.ogla.2026.01.014","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify clinical and demographic predictors of intraocular pressure (IOP)–lowering success following goniotomy in a large, generalizable cohort using the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight).</div></div><div><h3>Design</h3><div>Retrospective clinical cohort study.</div></div><div><h3>Participants</h3><div>Adults who underwent goniotomy between 2013 and 2022 in the IRIS Registry (n = 48 098).</div></div><div><h3>Methods</h3><div>Multivariable logistic regression and Cox proportional hazards models were used to evaluate predictors of short-term surgical success (defined as ≥20% IOP reduction without medication data) and long-term failure. Kaplan–Meier analysis assessed cumulative success rates. The mean IOP over 36 months were compared across glaucoma subtypes and disease severity.</div></div><div><h3>Main Outcome Measures</h3><div>redictors of short-term success and long-term failure; changes in mean IOP over 36 months.</div></div><div><h3>Results</h3><div>Among the 48 098 eyes, 52% achieved short-term success by 6 months. The mean IOP decreased from baseline 16.8 mmHg to 15.06 mmHg (10.4% decrease) after phacogoniotomy (n = 31 861) and from 21.28 mmHg to 15.26 mmHg (28.3% decrease) after standalone goniotomy (n = 3776) 36 months postoperatively. Higher baseline IOP, older age, male sex, severe glaucoma, concurrent cataract surgery, pseudoexfoliation glaucoma (PXG), and low-tension glaucoma (LTG) were independently associated with higher odds of short-term success and lower risk of long-term failure (all <em>P</em> &lt; 0.05). Postoperative pilocarpine use (assumed to be applicable to the surgical eye) conferred greater odds of short-term success but greater odds of long-term failure.</div></div><div><h3>Conclusions</h3><div>In this large national cohort, several demographic and clinical factors—including higher baseline IOP, more severe glaucoma, PXG, and LTG diagnoses—were predictive of goniotomy success. These findings suggest that goniotomy may benefit patient groups not traditionally prioritized for minimally invasive glaucoma surgery.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 418-430"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Quality of Reporting on Glaucoma Surgical Innovations during Early Development Stages Using Idea, Development, Exploration, Assessment, Long-term Follow-up (IDEAL) Guidelines","authors":"Chiara De Vitto MD,&nbsp;Valeria Dattilo MD,&nbsp;Gianni Virgili MD, PhD,&nbsp;Antonio Maria Fea MD, PhD,&nbsp;Julian Garcia-Feijoo MD, PhD,&nbsp;Augusto Azuara-Blanco MD, PhD","doi":"10.1016/j.ogla.2026.01.015","DOIUrl":"10.1016/j.ogla.2026.01.015","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Topic&lt;/h3&gt;&lt;div&gt;Glaucoma surgical practice has changed over the past 2 decades. We investigated how the earliest stages of glaucoma surgical innovations have been conducted and reported.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical Relevance&lt;/h3&gt;&lt;div&gt;Surgical innovations are crucial to improve patient care. However, developing novel techniques and devices presents unique challenges that make rigorous evaluation and reporting difficult. To support surgeons and researchers, the Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) collaboration has issued guidelines aimed at facilitating improvements in the conduct and reporting of surgical innovations at different stages.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We have considered all glaucoma surgical innovations introduced in the past 2 decades and searched for the initial reports of each technique, targeting “first-in-human” and first case series. We have searched for human studies in PubMed Central, Scopus, Google Scholar, Clinicaltrials.gov, and gray literature was also included. We used the IDEAL collaboration stages 1 (“idea”) and 2a (“development”) checklists to assess the quality of reporting. Checklists include items on study design, consenting, protocol availability, and ethical and regulatory approvals. The study protocol was prospectively registered at Open Science Framework.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;We identified 21 different techniques and devices. Among the 53 included studies, 22 were earliest reports (IDEAL stage 1) and 31 were categorized as development assessment (IDEAL stage 2a). The techniques most represented were trabecular dilatation or disrupting surgeries (25 studies), trabecular stenting (10 studies), and suprachoroidal devices (10 studies). In the IDEAL stage 1, 81.8% of studies identified the device or technique in the title or abstract or referred to the “first-in-human” experience, and 77.3% provided structured summaries, with detailed outcome measures. Technical feasibility was addressed in 63.6% of studies; however, only 9% explicitly described an informed consent process, and 59% lacked references to ethical approvals. In the IDEAL stage 2a, 77% of studies included structured summaries, and 70% discussed the need for evaluation in a prospective multicenter study. Clinical outcomes, adverse events, and modifications to techniques were reported in equal proportion (61.3%); furthermore, 70% discussed the feasibility of further evaluation. Nevertheless, only 13% detailed the informed consent process, and 80% omitted details of regulatory approvals. A pre-study protocol was available in only 1 study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Critical aspects of study design and reporting were frequently missing in early-phase surgical studies of glaucoma. The IDEAL framework offers a structured approach to bridge these gaps and improve the quality of glaucoma surgical innovation reporting.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Financial Disclosure(s)&lt;/h3&gt;&lt;div&gt;Proprietar","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 401-409"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for Ciliary Block after Cataract and Goniosynechialysis Surgery in Primary Angle-Closure Disease","authors":"Yao Ma MD,&nbsp;Zhiqiao Liang MD,&nbsp;Kun Lv MD,&nbsp;Zhi Li MD,&nbsp;Liusen Yang MD,&nbsp;Shihao Li MD,&nbsp;Aiguo Lv MD,&nbsp;Shaojun Wang MD,&nbsp;Shuning Li PhD,&nbsp;Li Qin PhD,&nbsp;Sujie Fan PhD,&nbsp;Dajiang Wang PhD,&nbsp;Chao Dai PhD,&nbsp;Huijuan Wu PhD","doi":"10.1016/j.ogla.2026.01.003","DOIUrl":"10.1016/j.ogla.2026.01.003","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify predictive factors for ciliary block (CB) following combined phacoemulsification, intraocular lens implantation, and goniosynechialysis (P+I+GSL) in patients with primary angle-closure (PAC) and primary angle-closure glaucoma (PACG).</div></div><div><h3>Design</h3><div>A multicenter retrospective study.</div></div><div><h3>Participants</h3><div>This study analyzed 66 eyes from 66 patients who underwent P+I +GSL between February 2022 and December 2024. Patients were categorized into 2 groups: those who developed CB (n = 33) and those who did not (n = 33). All participants were Chinese.</div></div><div><h3>Methods</h3><div>Preoperative biometric parameters obtained from ultrasound biomicroscopy and IOLMaster, along with intraoperative data, were analyzed. Univariable and multivariable logistic regression analyses were conducted to identify risk factors for CB.</div></div><div><h3>Results</h3><div>Compared to the non-CB group, patients who developed CB had shorter axial length (AL), narrower anterior chamber width (ACW), and thinner lenses (lens thickness [LT]) (<em>P</em> &lt; 0.05) preoperatively. Multivariable analysis identified reduced ACW (odds ratio = 0.049, <em>P</em> &lt; 0.05), decreased LT (odds ratio = 0.007, <em>P</em> &lt; 0.05), and lack of preoperative mannitol administration (odds ratio = 0.025, <em>P</em> &lt; 0.05) as significant predictors of CB. The optimal cutoff values for predicting CB were 11.72 mm for ACW and 4.84 mm for LT, with area under the curve values of 0.861 and 0.863, respectively.</div></div><div><h3>Conclusions</h3><div>Shorter AL, narrow ACW, thin lenses, and lack of preoperative mannitol administration are significant risk factors for CB following P+I+GSL in PAC and PACG patients. These findings highlight the importance of preoperative assessment of ACW and LT, along with the use of mannitol, which may help reduce the incidence of CB in high-risk patients.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 410-417"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of the 63-μm Gelatin Microstent Versus 45-μm Gelatin Microstent","authors":"Mohammad Javad Ghanbarnia MD,&nbsp;Ticiana De Francesco MD,&nbsp;Ahmed Abdelaal MD,&nbsp;Markus Lenzhofer MD, PhD,&nbsp;Ingeborg Stalmans MD, PhD,&nbsp;Francesco Oddone MD, PhD,&nbsp;Antonio M. Fea MD, PhD,&nbsp;Herbert Reitsamer MD,&nbsp;David B. Yan MD, MSc,&nbsp;Iqbal Ike K. Ahmed MD","doi":"10.1016/j.ogla.2026.01.016","DOIUrl":"10.1016/j.ogla.2026.01.016","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare 12-month effectiveness and safety of 63-μm gelatin microstent (Xen63) versus 45-μm gelatin microstent (Xen45).</div></div><div><h3>Design</h3><div>Multicenter, retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Two hundred eyes of 200 patients (100 in each Xen63 and Xen45 group), with or without phacoemulsification.</div></div><div><h3>Methods</h3><div>Consecutive patients undergoing 63-μm microstent implantation across 4 countries (Canada, Italy, Austria, and Belgium) were compared with matched controls who underwent 45-μm microstent implantation.</div></div><div><h3>Main Outcome Measures</h3><div>Primary outcome measure was the probability of complete success at 1 year: (1) no 2 consecutive intraocular pressure (IOP) &gt;14 or &lt; 6 mmHg with 2 lines of vision loss and (2) ≥20% reduction from decision IOP, without glaucoma medications or reoperations. Qualified success allowed glaucoma medications and laser trabeculoplasty. Secondary outcomes included success with upper IOP cutoffs of 17 and 21 mmHg, postoperative IOP and medications course, complications, interventions, and reoperations.</div></div><div><h3>Results</h3><div>Complete success favored 63-μm microstent (56.9% vs. 43.9%, <em>P</em> = 0.017), using IOP cutoff of 14 mmHg. The 45-μm microstent was associated with an increased hazard of failure compared with the 63-μm microstent (hazard ratio, 1.9; 95% confidence interval, 1.2–3.0). Complete success using IOP cutoffs of 17 and 21 mmHg in the 63- versus 45-μm group was 60.1% versus 53.9% (<em>P</em> = 0.156) and 60.1% versus 55.0% (<em>P</em> = 0.243), respectively. Qualified success was not significantly different between the 2 groups using any IOP threshold (<em>P</em> &gt; 0.05). At 12 months, the 63-μm group had significantly lower IOP (mean, 14.6 ± 7.6 vs. 15.8 ± 6.1 mmHg; <em>P</em> = 0.021) and medication count (0.6 ± 1.1 vs. 1.1 ± 1.5; <em>P</em> = 0.024). Postoperative needling was performed in 16.0% and 18.0% of 63- and 45-μm microstent-implanted eyes, respectively. Incidence of early postoperative choroidal effusion was higher in the 63-μm group (25.0% vs. 6.0%; <em>P</em> &lt; 0.001). Interventions (62.0% vs. 59.0%) and reoperations (21.0% vs. 15.0%) were comparable between the groups (<em>P</em> &gt; 0.050).</div></div><div><h3>Conclusions</h3><div>Xen63 demonstrated superior IOP-lowering effectiveness compared with its 45-μm variant in patients requiring more robust IOP targets. Xen63-implanted eyes experienced a higher incidence of early postoperative choroidal effusion, the majority of which were transient.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 440-453"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Flip Sides of Interventional Glaucoma","authors":"Ticiana De Francesco MD,&nbsp;Angelo P. Tanna MD,&nbsp;Iqbal Ike K. Ahmed MD","doi":"10.1016/j.ogla.2026.05.002","DOIUrl":"10.1016/j.ogla.2026.05.002","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 357-359"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148260579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the Rate of Retinal Nerve Fiber Layer and Visual Field Loss as Outcomes in Glaucoma Trials","authors":"Giovanni Montesano MD, PhD,&nbsp;David P. Crabb PhD,&nbsp;Giovanni Ometto PhD,&nbsp;David F. Garway-Heath MD","doi":"10.1016/j.ogla.2026.01.010","DOIUrl":"10.1016/j.ogla.2026.01.010","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to compare the statistical power of structural and visual field (VF) outcomes for randomized clinical trials (RCTs) in glaucoma.</div></div><div><h3>Design</h3><div>Analysis of retrospectively collected data.</div></div><div><h3>Participants</h3><div>Eighty-two patients with glaucoma were recruited to a test–retest study, during which up to 10 24-2 Swedish Interactive Thresholding Algorithm (SITA) Standard VF and circumpapillary retinal nerve fiber layer (cpRNFL) Spectralis OCT scans were collected in separate sessions over 3 months.</div></div><div><h3>Methods</h3><div>Eyes with at least 3 sessions with a reliable VF (false-positives &lt; 15%) and cpRNFL scan (quality index ≥ 25 dB) were selected (127 eyes, 68 patients) to model the test–retest variability and the structural floor effect. These estimates were combined with a published realistic structure–function progression model from the United Kingdom Glaucoma Treatment Study to simulate longitudinal RCTs (30% neuroprotective effect). Simulations only included data from eyes with early to moderate VF loss (mean deviation [MD], ≥–10 dB, 107 eyes, 65 patients). Simulations were repeated 5000 times to estimate sample size requirements to detect a significant difference (<em>P</em> &lt; 0.05) in the rate of change of MD and average cpRNFL thickness, estimated with a linear mixed-effects model. We also tested the power of a significant outcome with either metric (<em>P</em> &lt; 0.025). A supplementary analysis was performed including eyes with early VF loss only (MD ≥ –6 dB).</div></div><div><h3>Main Outcome Measures</h3><div>Sample size at 80% power for the linear rate of MD, cpRNFL, and their combination.</div></div><div><h3>Results</h3><div>At 80% power, the required sample size (patients [95% confidence interval]) was 38% smaller for the MD rate (292 [300–283]) than the cpRNFL rate (470 [481–459]). The sample size for the combined outcome was only marginally smaller than the MD alone (275 [283–268]). The supplementary analysis on eyes with early VF loss showed similar results.</div></div><div><h3>Conclusions</h3><div>Using realistic modeling of structure–function progression and test–retest data, MD progression showed higher statistical power cpRFNL as an outcome measure for clinical trials.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 390-400"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146042240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining Visual Field Trend Progression Criteria in Glaucoma","authors":"Jeremy C.K. Tan MD,&nbsp;Giovanni Montesano MD, PhD,&nbsp;Katharina Bell MD, PhD,&nbsp;Jonathan Crowston MBBS, PhD,&nbsp;David P. Crabb PhD","doi":"10.1016/j.ogla.2026.01.004","DOIUrl":"10.1016/j.ogla.2026.01.004","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the stability of visual field (VF) progression events and to evaluate strategies to reduce false-positive (FP) progression.</div></div><div><h3>Design</h3><div>Retrospective study.</div></div><div><h3>Subjects</h3><div>Two thousand one hundred thirty-three eyes of 2133 patients with 12 consecutive VF tests from five National Health Service glaucoma clinics.</div></div><div><h3>Methods</h3><div>A progression event was defined as a negative slope and <em>P</em> value &lt; 0.05. False-positive progression events (“reversions”) were defined as events where the <em>P</em> value fell below 0.05 at ≥ 1 visit and subsequently rose above 0.05 at a later time point. The impact of stricter probability thresholds (<em>P</em> &lt; 0.02, 0.01 and 0.005) and event assessment at later visits on FP progression was evaluated.</div></div><div><h3>Main Outcome Measures</h3><div>Frequency of FP progression events.</div></div><div><h3>Results</h3><div>Four hundred fifty-seven (21.4%) eyes had at least one reversion at the <em>P</em> &lt; 0.05 threshold, for a median interval of 2 visits. The mean rate of change at the time of apparent progression was –1.05 dB/year (95% confidence interval –1.19 to –0.92 dB/year). The proportions of eyes with FP progression events were significantly lower at stricter probability thresholds (13.7%, 9.9%, and 7.7% at <em>P</em> &lt; 0.02, &lt; 0.01, and &lt; 0.005, respectively; <em>P</em> &lt; 0.001). Using stricter thresholds conferred significantly lower hazards of FP progression (hazard ratio 0.60 for <em>P</em> &lt; 0.02, 0.42 for <em>P</em> &lt; 0.01, and 0.38 for <em>P</em> &lt; 0.005; all <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>A substantial proportion of apparent progression at the established <em>P</em> &lt; 0.05 threshold may be falsely positive. Using stricter probability thresholds and initiating event detection at later visits may improve progression specificity in clinical practice.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 372-379"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Vision-Related Difficulties in Low Light Levels and Visual Fields in Glaucoma","authors":"Maanasi Mahalingam MOptom,&nbsp;Jason Charng PhD,&nbsp;Vanessa T.S. Tang PhD,&nbsp;William H. Morgan MBBS, PhD,&nbsp;Geoffrey Chan MBBS (Hons), MMedSc,&nbsp;Andrew Turpin PhD,&nbsp;Allison M. McKendrick PhD","doi":"10.1016/j.ogla.2026.01.006","DOIUrl":"10.1016/j.ogla.2026.01.006","url":null,"abstract":"<div><h3>Objective or Purpose</h3><div>To determine whether self-reported visual challenges in low lighting are associated with binocular severity of 24-2 visual field (VF) loss in people with glaucoma.</div></div><div><h3>Design</h3><div>A cross-sectional study.</div></div><div><h3>Participants</h3><div>Data from 128 participants with primary open-angle glaucoma enrolled in the longitudinal cohort “Individualised Perimetry Progression Observations in Glaucoma Study” at Lions Eye Institute, Perth, Australia, were analyzed.</div></div><div><h3>Methods</h3><div>Monocular VFs were merged to form an integrated visual field (IVF) using the “best location method.” Visual field locations were divided into four regions: central, peripheral, superior, and inferior. The Low Luminance Questionnaire (LLQ) and Glaucoma Quality of Life-15 (GQL-15) were self-administered electronically. The associations between questionnaire scores and VF indices were assessed using linear regression, considering covariates of age, gender, lens status, and best eye visual acuity. Correlations between the composite and subscales of LLQ and GQL-15 were calculated.</div></div><div><h3>Main Outcome Measures</h3><div>Association between self-reported difficulties under low luminance and binocularly IVFs.</div></div><div><h3>Results</h3><div>Visual field indices were associated with log-transformed composite LLQ scores. Piecewise linear regression identified breakpoints at 21.7 decibels (dB) (95% confidence interval [CI]: 18.1–25.3 dB) and –6.3 dB (95% CI: –2.7 to –9.9 dB) for global integrated VF mean sensitivity and total deviation, respectively. Inferior IVF defects were associated with difficulties at low light levels, especially with driving, adjusting for age, gender, lens status, and better eye visual acuity. The composite and subscales of the LLQ and GQL-15 were moderately correlated.</div></div><div><h3>Conclusions</h3><div>Self-reported difficulties at low light levels were partially explained by binocularly IVF status in people with glaucoma. The LLQ identifies difficulties at low light levels, which are not captured by the standard clinical tests.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 454-463"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145992000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Technique for Intracameral Pressure Measurement in Clinical Practice","authors":"Parth R. Vaidya MD,&nbsp;Georgina Medina MD,&nbsp;Scott Kolesky MD, PhD,&nbsp;G. Baker Hubbard III MD,&nbsp;Deepta Ghate MD","doi":"10.1016/j.ogla.2026.01.005","DOIUrl":"10.1016/j.ogla.2026.01.005","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 477-478"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Glaucoma in India over 2 Decades and Projections to 2050","authors":"Selvaraj Jerrome MSc, MPhil,&nbsp;Balasubramaniam Niranjana MD,&nbsp;Sanil Joseph PhD, MPh,&nbsp;Thiruppathi Swathi MSc,&nbsp;Thandavarayan Kumaragurupari PhD,&nbsp;Vijayalakshmi A. Senthilkumar MS,&nbsp;Subbaiah R. Krishnadas DO, DNB","doi":"10.1016/j.ogla.2026.01.001","DOIUrl":"10.1016/j.ogla.2026.01.001","url":null,"abstract":"<div><h3>Topic</h3><div>This study synthesizes data on prevalence of glaucoma in India for the year 2020 and projects the disease burden through 2050.</div></div><div><h3>Clinical Relevance</h3><div>Robust, country-specific prevalence estimates are essential to inform public health policy, guide resource allocation, and support advocacy for glaucoma prevention and care in India.</div></div><div><h3>Methods</h3><div>We included population-based studies published between January 2000 and January 2024 reporting glaucoma prevalence among individuals aged ≥40 years in India. A systematic search was conducted in PubMed, Scopus, and Web of Science using keywords and MeSH terms related to glaucoma epidemiology. Two independent reviewers (N.B. and T.S.) screened articles using predefined criteria and extracted data. Risk of bias was assessed using the Joanna Briggs Institute's checklist. Pooled prevalence estimates were calculated using a random-effects restricted maximum likelihood model. A linear regression model projected future prevalence of glaucoma. Subgroup, meta-regression, and sensitivity analyses explored sources of heterogeneity (I²), and publication bias was assessed using Egger test.</div></div><div><h3>Results</h3><div>Out of 1657 identified articles, 13 studies with a cumulative sample of 50 671 participants were included in the meta-analysis. Study sample sizes ranged from 680 to 7438 participants. All included studies showed low risk of bias. The pooled glaucoma prevalence in India was estimated at 3.23% (95% confidence interval: 2.54–3.92; I² = 95.52), with subtype-specific prevalence of 2.07% for primary open-angle glaucoma (POAG), 0.81% for primary angle-closure glaucoma (PACG), and 0.29% for both secondary glaucoma and pseudoexfoliation glaucoma. Subgroup analyses revealed significant variation in prevalence by age, gender, geographic zone, habitation, and diagnostic criteria, ranging from 0.29% to 4.92%. Despite stratification, heterogeneity remained high (I² = 50.57–97.62). By 2050, overall glaucoma prevalence is projected to increase to 4.52% (a 28.77% rise), with PACG prevalence doubling and POAG rising by 18.26%. No publication bias was detected (Egger test, <em>P</em> = 0.2431).</div></div><div><h3>Conclusion</h3><div>Glaucoma poses a substantial public health challenge in India, with marked demographic and regional disparities. Strengthening prevention strategies, enhancing early detection, and addressing epidemiological data gaps are vital to mitigate the growing disease burden and inform public health responses.</div></div><div><h3>Financial Disclosures</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"9 4","pages":"Pages 464-476"},"PeriodicalIF":3.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}